3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Hematologic Neoplasms
5
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia
4
Hodgkin Disease
4
Breast Neoplasms
4
Leukemia, Myeloid, Acute
3
Recurrence
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, B-Cell
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Sarcoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphoid
1
Leukemia, Biphenotypic, Acute
1
Inflammatory Breast Neoplasms
1
Hematologic Diseases
1
Graft vs Host Disease
1
Colorectal Neoplasms
1
Burkitt Lymphoma
1
Interventions
Cetuximab
44
Oxaliplatin
39
Irinotecan
38
Fluorouracil
36
Capecitabine
36
Bevacizumab
36
pembrolizumab
35
Leucovorin
34
Nivolumab
21
Gemcitabine
17
regorafenib
13
Panitumumab
12
IFL protocol
12
Folfox protocol
12
Cyclophosphamide
12
Pemetrexed
11
Cisplatin
11
tislelizumab
9
Paclitaxel
9
HMPL-013
9
Carboplatin
9
130-nm albumin-bound paclitaxel
8
durvalumab
7
Specimen Handling
7
Docetaxel
7
trametinib
6
Trifluridine
6
Ipilimumab
6
Drug Therapy
6
trifluridine tipiracil drug combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colorectal Neoplasms
×
Mesna
×
Clear all
NCT07255664
2025-12-08
ProbeTILity
Curacell Holding AB
Phase 1/2
Recruiting
12 enrolled